High Purity Orlistat CAS 96829-58-2 Weight Loss Steroids Powder

High Purity Weight Loss Steroids Powder Orlistat for Slimming CAS 96829-58-2

Orlistat

Product Name: Orlistat 
Synonyms: (S)-2-FORMYLAMINO-4-METHYL-PENTANOIC ACID (S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYL ESTER;RO-18-0647;(-)-TETRAHYDROLIPSTATIN;ORLISTAT;N-FORMYL-L-LEUCINE (1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYL ESTER;XENICAL;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat 
CAS: 96829-58-2 
MF: C29H53NO5 
MW: 495.73 
Chemical Properties Off-White Solid 
Usage An antiobesity agent. A pancreatic lipase inhibitor. Antiobesity agent. 
Usage antidiabetic 
Usage Orlistat is an antiobesity agent. Orlistat is an pancreatic lipase inhibitor. 
Usage Tetrahydrolipstatin (orlistat) is a semi-synthetic derivative of lipstatin, a metabolite isolated from Streptomyces toxytricini. Tetrahydrolipstatin acts as a potent, irreversible inhibitor of pancreatic lipase. In vivo, it blocks the absorption of triglycerides while allowing fatty acid absorption. Tetrahydrolipstatin is widely used for the treatment of obesity. 
Biological Activity Hypolipemic pancreatic, gastric and carboxylester lipase inhibitor. Exhibits no activity at phospholipase A 2 , liver esterase, trypsin and chymotrypsin. Inhibits the thioesterase domain of fatty acid synthase, leading to cell cycle arrest at the G 1 /S boundary in vitro . Prevents the absorption of approximately one third of fat from food and exhibits progastrokinetic, antiobesity and antihypercholesterolemic activity in vivo . 

Orlistat  Description :

Orlistat is a non-systemic effects of anti-obesity drugs for specific gastrointestinal lipase inhibitor, combined with dietary restrictions can help promote weight loss and prevent weight regain. Gastrointestinal lipases break down fats in the gastrointestinal tract is necessary enzymes, orlistat inhibits stomach, pancreatic and hydroxy acid esterase, primarily through the stomach, small intestine lumen of the stomach and pancreatic lipases active serine parts form a covalent bond, to inactivate enzymes play a therapeutic role. Inactivate enzymes can not be fat in food (mainly triglyceride) hydrolysis of absorbable and non-esterified fatty acid monoacylglycerol. No decomposition of triglycerides (about 30% of the amount of feed) can not be absorbed in the intestine, thereby reducing caloric intake, body weight under control. Systemic absorption of the drug efficacy can play without going through. Orlistat for weight loss, and reduce the risk factors associated with obesity and other diseases associated with obesity (including high cholesterol, type 2 diabetes, impaired glucose tolerance, hyperinsulinemia, hypertension) in morbidity, and reduce the fat content of organs.

Orlistat (also known as tetrahydrolipstatin) is a drug designed to treat obesity. It is marketed as a prescription drug under the trade name Xenical by Roche in most countries, and is sold over-the-counter as Alli by GlaxoSmithKline in the United Kingdom and the United States.Its primary function is preventing the absorption of fats from the human diet by acting as a lipase inhibitor, thereby reducing caloric intake. It is intended for use in conjunction with a healthcare provider-supervised reduced-calorie diet.

Orlistat is the saturated derivative of lipstatin, a potent natural inhibitor of pancreatic lipases isolated from the bacterium Streptomyces toxytricini.However, due to its relative simplicity and stability, orlistat was chosen over lipstatin for development as an anti-obesity drug.

The effectiveness of orlistat in promoting weight loss is definite, though modest. Pooled data from clinical trials suggest that people given orlistat in addition to lifestyle modifications, such as diet and exercise, lose about 2–3 kilograms (4.4–6.6 lb) more than those not taking the drug over the course of a year.Orlistat also modestly reduces blood pressure, and appears to prevent the onset of type 2 diabetes, whether due to weight loss itself or to other effects; in a large randomized controlled trial, orlistat was found to reduce the incidence of diabetes by nearly 40% in obese people.

Orlistat is notorious for its gastrointestinal side effects (sometimes referred to as treatment effects), which can include steatorrhea (oily, loose stools). These decrease with time, however, and are the most frequently reported adverse effects of the drug.In the United States and the European Union, orlistat is available for sale without a prescription. Over-the-counter approval was controversial in the United States, with consumer advocacy group Public Citizen repeatedly opposing it on safety and efficacy grounds.Generic formulations of orlistat are available in some countries. In Australia it is listed as an S3 medication, which means its available over the counter in pharmacies.